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Background: Retroviral integrase catalyzes integration of viral DNA into the host genome. Integrase interactor (INI)
1/hSNF5 is a host factor that binds to HIV-1 IN within the context of Gag-Pol and is specifically incorporated into
HIV-1 virions during assembly. Previous studies have indicated that INI1/hSNF5 is required for late events in vivo and
for integration in vitro. To determine the effects of disrupting the IN-INI1 interaction on the assembly and infectivity
of HIV-1 particles, we isolated mutants of IN that are defective for binding to INI1/hSNF5 and tested their effects on
HIV-1 replication.
Results: A reverse yeast two-hybrid system was used to identify INI1-interaction defective IN mutants (IID-IN). Since
protein-protein interactions depend on the surface residues, the IID-IN mutants that showed high surface
accessibility on IN crystal structures (K71R, K111E, Q137R, D202G, and S147G) were selected for further study. In vitro
interaction studies demonstrated that IID-IN mutants exhibit variable degrees of interaction with INI1. The
mutations were engineered into HIV-1NL4-3 and HIV-Luc viruses and tested for their effects on virus replication. HIV-1
harboring IID-IN mutations were defective for replication in both multi- and single-round infection assays. The
infectivity defects were correlated to the degree of INI1 interaction of the IID-IN mutants. Highly defective IID-IN
mutants were blocked at early and late reverse transcription, whereas partially defective IID-IN mutants proceeded
through reverse transcription and nuclear localization, but were partially impaired for integration. Electron
microscopic analysis of mutant particles indicated that highly interaction-defective IID-IN mutants produced
morphologically aberrant virions, whereas the partially defective mutants produced normal virions. All of the IID-IN
mutant particles exhibited normal capsid stability and reverse transcriptase activity in vitro.
Conclusions: Our results demonstrate that a severe defect in IN-INI1 interaction is associated with production of
defective particles and a subsequent defect in post-entry events. A partial defect in IN-INI1 interaction leads to
production of normal virions that are partially impaired for early events including integration. Our studies suggest
that proper interaction of INI1 with IN within Gag-Pol is necessary for proper HIV-1 morphogenesis and integration.
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Retroviruses express Gag, Gag-Pol and Env as poly-
proteins. During late events, retroviral Gag and Gag-Pol
polyproteins assemble together within the producer
cells. Cleavage of the precursor polyproteins by the viral
protease during maturation leads to infectious virions
[1-3]. While Gag is the structural component essential
for assembly, genetic studies over more than a decade
have demonstrated that mutations in the Pol component
of the Gag-Pol polyprotein leads to defects in morpho-
genesis of particles that can manifest either as defects in
assembly and particle production or as defects in sub-
sequent rounds of infection. In HIV-1 and other lenti-
viruses, Pol protein consists of protease (PR), reverse
transcriptase (RT) and integrase (IN). IN catalyzes the
integration of viral DNA into host chromosomal DNA
by sequential steps of 3’ processing and strand transfer
[4]. Deletions or certain point mutations of IN (class II
IN mutations) while not affecting the catalytic activity of
integrase, lead to defects in stages other than integration
(termed pleiotropic effects) including viral protein syn-
thesis/stability, assembly and virus particle release, un-
coating, reverse transcription and nuclear localization
[5-15]. Similarly, certain mutations in RT have been
shown to significantly reduce assembly and virion re-
lease [16-18]. These results suggest that perturbing the
Pol portion of Gag-Pol can lead to defects in assembly,
morphogenesis and particle release, which can in turn
lead to production of non-infectious particles. However,
the role of Pol in mediating these late event defects or
the mechanism of these pleiotropic effects is poorly
understood. One possibility is that mutations in Pol
could interfere with Gag/GagPol multimerization or pro-
teolytic processing, giving rise to multiple effects [16,19].
Another possibility that has not been explored is that IN
and RT mutations may alter the interaction of Pol with
cellular proteins leading to defects in various stages of
HIV-1 replication.
Several cellular proteins interact with IN and RT. We
isolated the first IN-interacting cellular protein termed
Integrase interactor (INI)1/hSNF5 [20]. INI1 selectively
binds to HIV-1 IN within the context of Gag-Pol and is
specifically incorporated into HIV-1 virions during as-
sembly in the producer cells [21,22]. INI1/hSNF5 has
three highly conserved domains, the first two are imper-
fect repeats of each other (termed Rpt1 and Rpt2) and a
third domain termed homology region III (HR III) [23].
The Rpt1 domain is the minimal IN-interaction domain
of INI1 and it is necessary and sufficient to bind HIV-1
IN [23]. The Rpt2 domain harbors a masked nuclear ex-
port signal (NES), which when unmasked, allows nuclear
export of INI1 [24].
We have shown that INI1 plays a role in the late
events of HIV-1 replication including assembly andparticle production. Expression of a minimal IN-binding
fragment of INI1, termed S6, inhibits HIV-1 particle pro-
duction in a dominant negative manner [21]. The ex-
pression of S6 in HIV-1-producing cells leads to the
disruption of the IN-INI1 interaction resulting in a potent
(1000 to 10,000 fold) inhibition of HIV-1 particle produc-
tion [21]. Single amino acid substitutions in either S6 or
IN that abolish the mutual protein-protein interaction, ab-
rogate the inhibition [21]. Furthermore, deletion of IN
from Gag-Pol and expressing IN as a Vpr-IN fusion in
trans, abrogates S6-mediated inhibition. These results in-
dicate that the S6 directly binds to IN within Gag-Pol and
interferes with late stages of HIV-1 replication [21]. In a
separate study, we showed that S6 fragment inhibits the
post-translational early stages of HIV-1 assembly such as
Gag/Gag-Pol trafficking and processing [25]. Furthermore,
human cell lines lacking INI1 exhibit defects in HIV-1
particle production, and the expression of INI1 in these
cells restores particle production [26]. Together, these
studies highlight the importance of Gag-Pol interaction
with INI1 for proper assembly and particle production.
INI1/hSNF5 is a core component of the SWI/SNF
ATP-dependent chromatin-remodeling complex and
modulates integration activity in vitro [20]. Because of
its association with SWI/SNF, INI1 is thought to target
integration into open chromatin regions [20,27]. More-
over, recent studies demonstrate that INI1 within the
SWI/SNF complex is required for integration of HIV-1
DNA into chromatinized DNA targets in vitro [28].
INI1/hSNF5 is incorporated selectively into HIV-1, but
not into other retroviral particles, and IN is required for
this incorporation [22]. Binding of IN to INI1 also leads
to recruitment of other INI1 binding proteins into HIV-
1 virions. INI1 binds to SAP18 (Sin3a associated protein
of 18 KD), a component of the Sin3a-HDAC1 complex.
In addition to INI1, components of the Sin3a/HDAC1
repressor complex, including SAP18 and HDAC1, are
incorporated into HIV-1 virions [29]. HIV-1 particles
containing the catalytically inactive HDAC1H141A mutant
show reduced deacetylase activity and reduced infecti-
vity. The block due to the presence of the HDAC1H141A
mutant appears to be at or prior to reverse transcription
in the target cells [29]. These observations are corrobo-
rated by the findings that producer cells lacking INI1
show greatly reduced HIV-1 particle production and that
the few particles produced are defective for reverse tran-
scription [26]. These studies indicate that interactions of
INI1/hSNF5 and associated complex such as HDAC1 in
producer cells are necessary for HIV-1 particle produc-
tion and for the infectivity of those particles. These
studies collectively suggest that a defect in INI1 binding
could cause various defects during HIV-1 replication in-
cluding assembly and particle production, reverse tran-
scription and/or integration.
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action in HIV-1 replication, we isolated and character-
ized mutants of IN impaired for binding to INI1 using a
reverse yeast two-hybrid system. We characterized a
panel of mutants obtained in this screen by studying
their effect on various steps of HIV-1 replication. Our
analyses indicate that many mutants highly defective for
INI1 binding are severely compromised for replication
in vivo and are defective for early post-entry reverse
transcription. These mutants exhibit defective virion
morphology. Other mutants, partially defective for INI1
binding, although competent for reverse transcription,
are partially impaired for integration. Together with pre-
vious findings, our results suggest that the association of
INI1 with IN within the context of Gag-Pol is necessary
for the proper morphogenesis and for the production of
virion particles competent for infection.Results
Isolation and characterization of INI1-interaction-defective
(IID) IN mutants
To determine the consequences of disrupting the IN-
INI1 interaction on HIV-1 replication, we sought to iso-
late mutants of IN that are defective for binding to INI1.
Mutants were selected using a reverse yeast reverse two-
hybrid system. A random mutation library of IN fused
to GAL4 activation domain (GAL4AC-IN*, [30]) was
screened against the wild type full-length INI1 fused to
LexA DNA binding domain (LexADB-INI1). As expec-
ted, INI1 wild type controls interacted strongly to wild
type IN, resulting in LacZ expression and blue colonies.
Screening of mutant IN library against LexADB-INI1
resulted in several white colonies. Plasmids expressing
GAL4AC-IN* mutants were isolated from these colonies
and were retransformed into yeast along with LexADB-
INI1 to confirm their interaction-defective phenotype.
These GAL4AC-IN* clones were also tested for their
ability to dimerize with LexADB-IN. Those clones that
retained the interaction with LexADB-IN (thus able to




IN dimer IN tetram
A B A B
K71 118 79 90 94
K111 65 81 122 115
Q137 71 102 59 56
S147 71 N/A N/A N/A
D202 71 61 68 50
aDetermined using PISA program based on IN crystal structures of dimer and tetram
bDetermined using HIV Sequence Compendium (2010).were selected for further analysis and were termed INI1-
Interaction Defective-IN clones (IID-IN). Sequence ana-
lysis of eleven clones isolated from this screen, which
were defective for binding to INI1 but not for binding to
IN, revealed the presence of one or more substitution
mutations (Additional file 1: Table S1). The mutated res-
idues spanned all domains of IN, with most mapping to
the core domain. Among these mutations the previously
published INI1-interaction defective mutant, K71R, that
retains 40% binding to INI1, was also identified (see
Table 1, [31]). Since surface residues are most likely to
be engaged in protein-protein interactions, we analyzed
the surface accessibility of the parent residues that were
mutated in the IID-IN clones by using the Protein In-
terfaces Surfaces and Assemblies (PISA) program [32].
Five different mutated residues that showed high sur-
face accessibility (>50) were chosen for further analysis
(Table 1). A previously characterized IN mutant, H12Y,
was used as a control in all the subsequent experi-
ments (the H12 residue is not surface accessible).
Mapping of surface residues on solved crystal struc-
tures of the IN dimer and tetramer (PDB: 1ex4 and
1k6y respectively [33,34]) revealed the presence of pa-
rent residues along one face of the IN monomer, im-
plicating this surface as being involved in INI1 binding
(Figure 1B). One of the positions, S147, is located on the
disordered flexible loop and hence could not be mapped
on the crystal structure.
Since INI1 selectively binds to HIV-1 IN but not to
other primate lentiviral or retroviral INs [22], we exam-
ined the relative conservation of IID-IN residues among
HIV-1 and the closely related SIVcpz strains, or among
other primate lentiviruses using the 2010 HIV-1 sequen-
ce compendium. All IID-IN parent residues displayed at
least 90% identity among HIV-1 and SIVcpz strains, but
exhibited varying degrees of conservation among IN
proteins from other primate lentiviruses (Table 1 and
Figure 1A). Most notably, the residue D202 was invari-
ant among HIV-1 and SIVcpz IN sequences, however, in
the majority of other primate lentiviruses, D202 is re-
placed by asparagine (N). This analysis indicated thation of IN residues implicated in INI1 binding
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Figure 1 IID-IN mutants map to surface of IN crystal structures and exhibit defects in binding to INI1 in vitro: A. A cartoon illustrating
the positions of IID-IN mutations on three domains of IN (not drawn to scale). NTD = N-terminal domain; CCD = Central core domain;
CTD = C-terminal domain. Sequence spanning the mutant residues from HIV-1 and three other related lentiviruses are indicated below the
cartoon, and the parent residues that are mutated is shown in red. B. Mutant residues with high surface accessibility are highlighted on Pymol
rendition of two domain crystal structures of IN. The left diagram illustrates the structure of a dimeric core + C-terminal domains (PDB: 1EX4); and
the right diagram illustrates the tetramer formed by the core + N-terminal domains (PDB: 1K6Y). Residues are indicated in the following colors:
D202- green, K111- blue, Q137- red, K71- cyan. Monomers within the IN dimer and tetramer are represented by different colors. C. IID-IN mutants
are defective for binding to INI1 in vitro. In vitro GST pull-down assays were performed by using 293 T cell lysates expressing YFP-WT IN or
YFP-IID-IN mutants. Lysates were normalized for YFP-IN (WT or IID-IN mutant) expression and bound to GST-INI1 immobilized onto glutathione
sepharose beads. GST-INI1 input was measured by Coomassie stain. WB =Western blot. D. Graphic representation of degree of binding of each
YFP-IID-IN mutant relative to that of YFP-WT, as measured by densitometric analysis. Amount of YFP-IN bound was normalized against amount of
YFP-IN loaded.
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among HIV-1 INs but are not as conserved among other
lentiviruses.IID-IN mutants are defective for INI1 binding in vitro
To confirm the interaction defects of IID-IN mutants, a
GST-pull down assay was performed using mammalian
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lized for YFP-IN levels, and bacterially expressed GST-
INI1 bound to G-beads. The results of the pull down
assay confirmed that all IID-IN mutants were defective
for binding to INI1. Furthermore, these mutants could
be categorized into two groups: (1) Mutants that were
highly defective for INI1 binding, including H12Y (previ-
ously identified), Q137R, and D202G; and (2) mutants
that displayed partial binding, including S147G and
K71R (Figure 1C and D). K111E failed to express high
enough protein levels in mammalian cells to be tested
for INI1 binding in this system. However, in vitro bin-
ding of His6-K111E with GST-INI1 revealed ~60% bin-
ding compared to His6-WT (data not shown).
HIV-1 viruses harboring IID-IN mutants are defective for
replication
To determine the effect of IID-IN mutants on HIV-1
replication, these mutants were incorporated into the
full-length HIV-1NL4-3 molecular clone, and the wild
type and mutant virions were tested for their ability to
replicate in multi-day replication assays. Mutant virions
were produced in 293 T cells by transfection. Measure-
ment of total intracellular and virion-associated capsid
levels revealed no significant defect in level of p24
production (Additional file 2: Figure S1). Normalized
amounts of NL4-3 WT and mutant virions (25 ng of
p24) were used to infect CEM-GFP cells, a reporter
T-cell line containing integrated LTR-GFP. Viral repli-
cation was monitored over a course of 16 days by ob-
serving cellular GFP expression levels and quantifying
p24 in the culture supernatant. GFP expression of cul-
tures infected with WT NL4-3 reached a maximum level
at 14 days, indicating that viral replication peaked at
around this time (Figure 2A). Viruses harboring H12Y,
Q137R, and D202G, IID-IN mutations that were severely
impaired for INI1 binding were highly defective for
replication as very little GFP expression above basal
levels was observed at peak points in these cultures
(Figure 2A). While the replication of mutants K71R,
S147G, and K111E, which bore partial binding to INI1,
peaked at 14 days, the overall GFP levels were lower
than that of cells infected with WT virus, indicating a
partial defect in replication of these viruses.
Measurement of p24 levels in the infected CEM-GFP
culture supernatants corroborated the GFP expression
data (Figure 2B). H12Y, Q137R, and D202G, mutants
that were highly defective for inducing GFP expression,
exhibited background levels of p24 in the culture super-
natants. K71R, S147G and K111E mutants that exhibited
a partial defect in inducing GFP expression, demon-
strated a partial defect in p24 production. These mutants
expressed very low levels of p24 that steadily rose during
the course of infection, but overall lower than that of theWT. After about 12 days, the partially defective mutants
displayed an increase in p24 production. Our analysis of
the peak cultures (after 16 days) from one of the par-
tially defective mutants, S147G, indicated that the IN
mutation in these virions had been reverted to wild type
(data not shown). Of the partially defective mutants,
K71R appeared to be the most defective in multi-round
replication, however, the p24 levels of this mutant also
rose during the infection time course and reached levels
above background. Taken together, these studies indi-
cated that all IID-IN mutants exhibited defects in multi-
day replication.
To determine if the reduced infectivity of the mutant
viruses is due to a defect in early events, a single cycle
infection assay using a VSVG pseudotyped HIV-Luc re-
porter virus was performed. In this system, infection and
integration of HIV-Luc virus leads to expression of the
luciferase gene, allowing for measurement of infectivity.
HeLa cells were infected with normalized amounts of
WT and IID-IN mutants (5 ng p24) for 24 hours, cells
were harvested after infection and total protein and luci-
ferase activity was determined. Corroborating the multi-
round replication data, all mutants highly defective for
binding INI1 were severely (200-1,000 fold compared to
WT) impaired for infection, while mutants bearing partial
INI1 binding were partially (~2-20 fold compared to WT)
defective for infection (Figure 2C). Taken together, these
data suggested that the degree of defect in INI1 binding
was reflected in the degree of replication impairment.
Highly-defective IID-IN mutants are impaired for early
and late reverse transcription in vivo
The data from the single-round replication assay sug-
gested that the block to infection of IID-IN mutants oc-
curred at some step during early events. Since mutants
of both HIV-1NL4-3 and HIV-Luc, which carry different
envelope proteins and have different modes of entry,
were defective for infection, we surmised that the block
in replication was unlikely to occur at entry. We there-
fore tested for the ability of these mutants to undergo
post entry events including early and late reverse tran-
scription (RT), nuclear localization, and integration to
identify the stage at which these mutants were blocked
during replication in vivo.
To determine the effect of mutations on minus strand
strong-stop (early RT) and second-strand transfer (late
RT), cells were infected with 20 ng p24 of WT and
IID-IN HIV-Luc mutant viruses. Total DNA was col-
lected over a time course of infection (0-24 hours) and
subjected to quantitative real time PCR (qPCR) using
primers that specifically amplify early or late RT prod-
ucts. The WT virus revealed a sharp increase of early
and late RT products at 2 and 6 hours post-infection,
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Figure 2 IID-IN mutants are defective for multi-round and single-round replication: A. Fluorescence microscopic images of CEM-GFP cell
cultures infected with HIV-1NL4-3 carrying WT IN or IID-IN mutants in a multiday infection. CEM-GFP cells were infected with normalized amounts
of HIV-1NL4-3 (25 ng p24) WT or IID-IN mutants. Cultures were imaged for expression of LTR-GFP every 48 hr over a 16-day course of infection.
B. Measurement of virus particle release in the culture supernatant by p24 ELISA. Culture supernatants were collected from CEM-GFP cells infected
with normalized amounts of HIV-1NL4-3 virus harboring WT or IID-IN mutant IN, every 48 hr and measured for p24 levels. Green = IID-IN mutants
partially defective for INI1 binding; Red = IID-IN mutants highly defective for INI1 binding. Data is representative of two independent experiments.
C. Infectivity of HIV-Luc virus harboring WT IN or IID-IN mutations. Graph illustrates luciferase activity induced by infection of HeLa cells with HIV-Luc
WT and IID-IN mutants in a single round of infection. HeLa cells were infected with 5 ng p24 of WT or IID-IN mutant HIV-Luc. The infectivity was
quantified by measuring luciferase activity 24 hours post-infection. Data represents average of three independent experiments (Mean +/- SEM).
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D202G mutants all showed severe defects in both ear-
ly and late RT product formation compared to WT
(Figure 3A and D). While WT infection led to a clear
time-dependent rise and fall of RT products, the highly
defective IID-IN mutant RT product levels showed a
premature increase at 2 hr. time point and quickly
returned to baseline by 6 hr. and subsequent time points
during infection (Figure 3A and 3D).The partially defective IID-IN mutants, K71R, S147G,
and K111E were also tested for early or late RT product
formation. The partially defective mutants S147G and
K111E were not defective for early (Figure 3B) or late
RT (Figure 3E). However, K71R mutant exhibited a par-
tial defect in early RT and more significant defect in late
RT (Figure 3B and 3E). Analyses of early and late RT
products at 6 hrs. post-infection indicated that the











































































































































































































































































































































Figure 3 (See legend on next page.)
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Figure 3 IID-IN mutants are defective for early post entry events. A-C. Effect of IID-IN mutations on early RT. Using genomic DNA from 293T
cells infected with HIV-Luc harboring WT-IN, IID-IN, or catalytic mutant D116A, early RT products were quantified by qRT-PCR at indicated times
post-infection. Effects of highly defective IID-IN mutants on early RT are shown in (A) and partially defective mutants in (B). C. Relative effect of
IID-IN mutations on early RT as compared to WT. Data represents amounts at 6 h post-infection averaged from three independent experiments
(Mean +/- SEM). D-F. Effect of IID-IN mutations on late RT. As in panels A-C, late RT products in infected cells were quantified via qRT-PCR at
indicated times post-infection. Effects of highly defective IID-IN mutations on late RT are shown in (D) and partially defective mutants in (E).
F. Relative effect of IID-IN mutants on late RT as compared to WT. Data represents amounts at 6 h time post-infection averaged from three
independent experiments (Mean +/- SEM). G-I. Effect of IID-IN mutations on formation of 2LTR circles. 2LTR products in infected cells were
quantified via qRT-PCR at 12 h post-infection. The data represents average of three independent experiments (Mean +/- SEM). Effects of highly
defective IID-IN mutations on 2LTR circle formation are shown in (G) and partially defective mutations in (H). I. Relative effect of IID-IN mutations
on 2LTR circle formation as compared to WT. Data represents amount of 2LTR products at 12 h post-infection averaged from three independent
experiments (Mean +/- SEM). J. The effect of IID-IN mutations on integration. Alu-Gag products were quantified in infected cells via qRT-PCR at
24 hours post-infection. Data are compared to WT and represents average of three independent experiments (Mean +/- SEM).
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partially defective mutants, the K71R mutant exhibited
an intermediate phenotype, in that it was ~2.5 fold de-
fective for early RT (Figure 3C), and ~3.5 fold defective
for late RT (Figure 3F). The remaining two mutants,
S147G and K111E, did not exhibit significant defects in
early or late RT (Figure 3C, 3F).
Effect of IID-IN mutations on nuclear localization
We next examined the ability of mutants for nuc-
lear localization, by measuring 2LTR circle formation
(Figure 3G-I). 2LTR products peaked at 12 hours
post-infection for WT, Q137R and D202G viruses
(Figure 3G). The defect was most dramatic for H12Y,
which had no detectable levels of 2LTR circles (Figure 3G
and I). Analysis of the 2LTR formation by all the mutants
at the peak level (12 hrs.) as compared to WT indicated
that Q137R, D202G and K111E exhibited partial reduc-
tion in 2LTR circle formation (Figure 3I). However, K71R
and S147G mutants exhibited no significant defect in
2LTR formation (Figure 3I).
For all the above experiments of determining early and
late RT and 2LTR circle formation, we used the Class I
catalytic mutant, D116A, specifically defective for inte-
gration, as control. This mutant displayed no significant
defect in early and late RT, however, exhibited several
logs increase in 2LTR circle formation, consistent with
previous reports (Figure 3C, F and I). These studies
together indicated that while highly defective IID-IN
mutants are defective for early and late RT, and conse-
quently for 2LTR formation, the partially defective mu-
tants were not defective for early post entry events.
Partially defective IID-IN mutants are defective for
integration
We next examined the ability of all the mutants for inte-
gration in vivo using Alu-Gag real-time quantitative
PCR (Figure 3J). The two mutants Q137R and D202G
were severely impaired for integration; the remaining
mutants K71R, S147G and K111E exhibited partialdefect in integration that was correlated to their impair-
ment in binding to INI1. We were able to purify S147G
and K111E and found that they retained their ability to
carry out in vitro strand transfer activities, indicating that
the catalytic activity of these mutants was unaffected (data
not shown).
IID-IN mutants display aberrant virion morphology
The above data indicated that while highly defective IID-
IN mutants were impaired for early and late RT as well
for the subsequent events of replication in the target
cells, the partially defective IID-IN mutants were able to
pass through early and late RT, but were partially defect-
ive for integration. Since INI1 has a role in late events of
HIV-1 replication, we surmised that one reason for the
observed defects in reverse transcription of IID-IN mu-
tants was due to lack of proper Gag-Pol-INI1 interac-
tions leading to aberrant assembly and maturation of
particles, which in turn may lead to defects in post-entry
events. To investigate this possibility, we examined the
IID-IN mutants for: (i) viral protein processing in the
producer cells; (ii) incorporation of RT and IN into vi-
rions; and (iii) virion particle morphology using trans-
mission electron microscopy (TEM).
To determine the viral protein processing, total cel-
lular lysates of producer cells transfected with either the
wild type or mutant HIV-1NL4-3 were probed with
α-HIV-1 serum. All IID-IN mutants exhibited WT pat-
terns of viral protein levels and processing in producer
cells, except for H12Y (Figure 4A and B), which
exhibited the presence of an additional α-p24 antibody-
reactive band that migrated between 26 and 37 kDa
(Figure 4A). These results indicated that while H12Y
mutant exhibits a slightly defective processing, the re-
maining IID-IN mutants undergo normal protein pro-
cessing in producer cells.
Immunoblot analysis of mutant virus preparations nor-
malized for p24 revealed incorporation of normal levels
of viral proteins into virions, comparable to that of WT
































































































Figure 4 IID-IN mutants exhibit normal viral protein processing encapsidation of RT and IN into virions: A and B. Immunoblot analysis of
intracellular viral proteins. 50 ug of total protein from 293 T producer cells transfected with HIV-1NL4-3 WT or IID-IN mutants were separated on a
15% SDS-PAGE gel and transferred to nitrocellulose. The blots were probed with human patient sera. C. Immunoblot analysis of incorporation
of viral proteins. Total protein lysates from 350 ng (p24) of HIV-1NL4-3 WT or mutant virions were separated by SDS-PAGE, transferred onto
nitrocellulose and probed for the presence of IN, RT, and p24 using antibodies specific to each protein. D. Immunoblot analysis to determine the
levels of endogenous INI1 in cells expressing IID-IN mutant viruses. Total protein from 293 T producer cells transfected with HIV-1NL4-3 WT or
IID-IN mutants were probed with α-INI1 antibodies. The same blot was probed with α-GAPDH antibody as loading control.
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pared to that of WT, indicating that the dramatic defect in
early events is not due to defects in incorporation of IN
and RT. The H12Y mutant showed decreased levels of in-
corporation of IN and displayed higher levels of unpro-
cessed Gag proteins within the virions including Pr55 and
Pr41 (Figure 4C). This pattern was similar to the pattern
observed in virus deleted for IN (see Figure 4C). Further-
more, there were no appreciable defects in the level of RT
proteins. Thus, the defects in reverse transcription among
highly defective IID-IN mutants and the integration defect
observed in partially defective mutants do not appear to
be due to abnormal processing of viral proteins in the pro-
ducer cells or to low levels of viral proteins within the vi-
rions. We also determined the endogenous levels of INI1in cells expressing IID-IN mutants. As shown in Figure 4D,
the endogenous levels of INI1 did not drastically change
as a result of expression of HIV-1 harboring IID-IN mu-
tants. Therefore, our results indicate that the defective ac-
tivity of IID-IN mutants in the cells and viruses reflect
their defective interaction with INI1, rather than changes
in the levels of IN mutants or INI1 in the host cell.
To determine if the defects observed for the IID-IN
mutants correlated with defects in morphology, we car-
ried out ultra-structural analysis of cells producing
these virions by using transmission electron microscopy
(TEM). We examined 70-100 virions from about 7-12
infected cells each, for the presence of mature and im-
mature virions of different morphology and determined
the percentage of virions with conical, centric, acentric,
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rions at various stages of budding and morphogenesis
were readily observed in cells producing the wild type
virions. The mature virions exhibited typical cone shaped


























Figure 5 Ultrastructural analysis of producer cells expressing IID-IN m
mutants were fixed 6 hours post-media change in buffer containing 2.5% g
were imaged on a JEOL 1200EX and images were captured at ×20,000 ma
B. Quantitation of virion morphologies from various IID-IN mutants. Morph
or wild-type.partially defective IID mutants (K111E and S147G) ex-
hibited normal capsid morphology very similar to that of
the wild type (Figure 5A). Interestingly, the highly defec-
tive IID-IN mutants exhibited gross defects in morpholo-












utants: A. 293 T cells transfected with pNL4-3 harboring WT or IID-IN
lutaraldehyde and post-fixed with 1% osmium tetroxide. Cut sections
gnification. Insets are zoom-in images of representative virions.
























































































Figure 6 IID-IN mutant virions are not defective for RT activity
and in vitro uncoating: A. Graphic representation of exogenous RT
activity in IID-IN mutant virions. Viral lysates from 500 ng p24 each
of HIV-1NL4-3 WT and IID-IN mutant virions were tested for in vitro RT
activity using a poly-rA template, oligo-dT primer, and dNTPs in the
presence of 32P-dTTP. RT activity was determined by incorporation
of radiolabeled dTTP and measured by CPM in each reaction.
Data represents average of three independent experiments
(Mean +/- SEM). B. Quantitation of CA levels in cores purified from
wild type and IID-IN mutant virions. Cores were isolated from
concentrated virion suspensions by detergent treatment and density
gradient ultracentrifugation, and the levels of core-associated CA
were quantified as a percentage of the total CA protein in each
gradient. Shown are mean values from three independent
experiments; error bars represent SEM. C. Kinetic assay of HIV-1
uncoating in vitro. Purified cores were incubated at 37°C at indicated
times prior to pelleting by ultracentrifugation, and the levels of CA
in the supernatants and pellets were quantified by p24 ELISA.
Shown are mean values from three independent experiments; error
bars represent SEM.
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and B). The mutant D202G, although demonstrated pre-
sence of mature particles, exhibited the presence of signifi-
cant acentric crescent like particles (Figure 5B). In case of
D202G, about 25% of the particles exhibited acentric cres-
cent shaped, or immature or aberrant cores (Figure 5B).
H12Y virions exhibited the presence of immature par-
ticles, which were very similar to that of ΔIN virions
(Figure 5A). These results indicated that the degree of
INI1 interaction defects correlated to the severity of the
defect in virion morphology.
The virions harboring IID-IN mutations are not defective
for RT activity and uncoating in vitro
Since IN binding to RT has shown to play a role in re-
verse transcription and uncoating, a defect in early re-
verse transcription in vivo could be due to defects in
reverse transcriptase activity, uncoating or both
[14,35,36]. Therefore, to determine these possibilities, the
reverse transcriptase activities of IID-IN mutant viruses
were tested in an exogenous RT assay using normalized
amounts of WT and mutant HIV-1NL4-3 virions [22]. We
found that all the mutants exhibited significant levels of
RT activities in vitro indicating that the RT enzyme within
the mutant virions is functional (Figure 6A).
We next tested ability of mutants to undergo un-
coating by examining alterations in capsid stability in
vitro. Uncoating assays were carried out in vitro with
cores isolated from the WT and mutant HIV-1NL4-3 par-
ticles. HIV-1 cores were purified by the detergent “spin-
thru” approach as previously described [37]. Cores were
recovered from the gradients and tested in a standard
in vitro uncoating assay. We found that presence of IID-
IN mutations had only small effects on the levels of CA
associated with the purified HIV-1 cores (Figure 6B).
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coating using purified cores. Upon incubation at 37°C,
the wild type and mutant cores released CA protein into
a soluble form at comparable rates, indicating that the
mutants do not exhibit any defects in uncoating in vitro
(Figure 6C). Collectively, these results indicated that
cores isolated from mutant virions were not defective
for reverse transcriptase activity and that the mutations
did not markedly alter the intrinsic stability of the viral
cores.
IID-IN mutant interactions with other IN binding partners
Since IID-IN mutants were blocked for reverse tran-
scription and integration, we sought to determine if they
were also impaired for binding to other IN-interac-
ting proteins such as LEDGF, GEMIN2, and SAP18
[29,38,39]. His6-tagged WT and IID-IN mutants were
each tested for their ability to bind to GST-tagged host
proteins. Beads bound to GST alone failed to pull down
His6-tagged IN proteins (Figure 7A). All IID-IN mutants
bound to GST-SAP18 at levels comparable to WT, ex-
cept for Q137R which exhibited ~4-fold decrease in
SAP18 binding (Figure 7B and C). The IID-IN mutants
bound LEDGF close to or at WT levels (Figure 7D
and E). None of the mutants displayed defects in binding
to GEMIN2 (Figure 7F and G). Previous results demon-
strated that IN binds to RT and that both p66 and p51
are able to bind to IN equally efficiently in vitro [35].
Since highly defective mutants, Q137R and D202G were
defective for in vivo reverse transcription, these mutants
were also tested for their ability to bind GST-RT-p51
and GST-RT-p66. Our results indicated that while
Q137R displayed ~45% RT binding, D202G bound RT at
levels close to WT (~80% binding compared to WT)
(Figure 7H and I). In summary, among the IID-IN
mutants, Q137R showed defect in binding to SAP18,
LEDGF, and RT but no defect in binding to GEMIN2.
Interestingly, the mutant D202G, one of the highly de-
fective IID-IN mutants, exhibited significant binding to
all tested host factors including SAP18, LEDGF and
GEMIN2, as well as to RT, indicating that the strongest
defect observed for this mutant correlated with its defect
in binding specifically to INI1.
Discussion
Many IN mutants exhibit defects at stages other than in-
tegration including uncoating, reverse transcription, nu-
clear localization, assembly, and particle production
[5-15]. These pleiotropic defects of IN mutants are poor-
ly understood. However, since IN binds to various cellu-
lar proteins, we hypothesized that at least some of these
pleiotropic effects could be explained by the inability of
mutants to interact with host factors required for var-
ious stages in the HIV-1 life cycle. The results of ouranalysis of IN mutants defective for binding to INI1 (IID
mutants) indicate that lack of binding to INI1 could lead
to defects in many steps of HIV-1 replication. We have
summarized the results of our analysis in a table provid-
ing the % activity of the mutants relative to wild type IN
at various stages of HIV-1 replication (Table 2).
The parent residues of IID-IN mutations are located
largely along one face of the IN monomer and map pri-
marily to the catalytic core domain, corroborating the
previous idea that core domain is the major site of INI1-
IN interaction [20]. Many of the IN residues identified
as being involved in INI1 binding are highly conserved
among HIV-1 and SIVcpz, but are less conserved among
IN proteins from other lentiviruses, including SIVmac,
HIV-2 and HTLV-1. Specifically, the D202 residue is in-
variant among HIV-1 and SIVcpz, and this residue is re-
placed by an Asn (N202) at the same position in the
majority of other primate lentiviruses. The invariant na-
ture of the D202 residue in HIV-1 and SIVcpz, the pre-
sence of a different residue, N202, in the other primate
lentiviruses, combined with the observation that INI1
binds to HIV-1 IN but not to other lentiviral INs, raises
the possibility that D202 is a key residue which deter-
mines interaction of INI1 with HIV-1 IN. Future crystal-
lographic and molecular studies might shed light on this
hypothesis, which are beyond the scope of this report.
Our observation indicates that the degree of IN-INI1
binding correlates well with the level of viral replication,
in that mutants H12Y, Q137R and D202G, severely im-
paired for INI1 binding, are dramatically impaired for
replication in both multi- and single-cycle infection as-
says (Figure 2). While Q137R exhibits defect in several
protein-protein interactions, D202G is not significantly
defective for interaction with WT IN or with the other
known IN-binding proteins tested (LEDGF, SAP18,
GEMIN2 or RT, Figure 7), but is severely defective for
binding to INI1 (Figure 1). These mutants were highly
defective for early and late reverse transcription in vivo.
However, the mutant virions exhibited no defects either
in reverse transcriptase activity or the uncoating activity
in vitro (Figure 6). Electron microscopic analysis of mu-
tant particles indicated that H12Y and Q137R mutants
have highly aberrant virion morphology. While H12Y
mutants exhibit immature virion morphology, Q137R
and D202 virions exhibit varying degree of defects in
morphology and accumulate mixture of virions that have
acentric crescent shaped, or immature or aberrant cores
(Figure 5). These results indicate that mutants that are
severely defective for binding to INI1 exhibit aberrant
virion morphology.
It is interesting to note that while the capsid mor-
phology is affected by the presence of IID-IN mutations,
these capsids are stable. The relationship between the









































































































































































































Figure 7 Protein-protein interactions of IID-IN mutants with RT and various IN binding host factors. In vitro pull-downs of IID-IN mutants
with GST-tagged IN binding partners were carried out using His6-tagged IN (WT or IID-IN mutants) and GST (A), GST- SAP18 (B and C), GST-LEDGF
(D and E), GST-GEMIN2 (F and G), and GST-RT (H and I). 5μg of GST-tagged proteins were used for each pull-down reaction. Left side panels
(A, B, D, F and H) illustrate Western and Coomassie stained gel to indicate amount of loaded and bound proteins from a representative experiment.
Right side panels (C, F, G and I) illustrate graphic representation of relative binding of IID-IN mutants compared to that of WT. Quantitation of
binding was carried out by normalizing against total IN loaded for each reaction (C, E, G, I). The graphs (C, E, G and I) represent averages of three
independent experiments (Mean +/- SEM).
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where CA (p24) mutants show aberrant morphology due
to altered stability of the capsid [40,41]. There are se-
veral reports of the presence of aberrant morphology of
capsids when IN protein is mutated (class II IN mu-
tants). However, these studies do not report the capsid
stability. Furthermore, in a report using C130S IN muta-
tion it was demonstrated that capsid was unstable [5],
but the morphology of the mutant capsid was not de-
scribed. Here we have studied both capsid morphologyand stability, and have found that mutations in IN can
alter the morphology but not the stability of the capsid.
We surmise that mutations of residues within CA can
alter the intermolecular interactions and thereby affect
the stability of the capsid in addition to altering its
shape. However, mutations in IN may influence protein-
protein interactions during capsid assembly and matur-
ation, causing abnormal morphology but not necessarily
affect the intermolecular interactions within the ma-
ture capsid. Therefore, our results, albeit unexpected,
Table 2 Summary of effect of IID-IN mutations on various stages of HIV-1 replication relative to that of the wild type
Mutation












formation (at 12 hr.)
Integration
(at 24 hr.)
IN (WT) 100 100 100 100 100 100 100
H12Y 20.60 0.12 0.07 11.12 7.15 0 0
Q137R 10.00 0.09 0.40 29.89 12.10 30.62 5.42
D202G 32.00 0.09 0.14 14.71 14.74 48.58 1.34
K71R 46.00 3.74 2.52 38.13 27.73 150.78 61.64
S147G 77.00 29.83 6.93 74.01 124.82 164.75 33.29
K111E ND 29.26 4.68 71.25 104.25 47.07 65.30
D116A ND 0.11 3.36 79.39 60.15 13369.26 1.44
a % activity of mutants was determined by considering the activity of wild type as 100%.
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to have a morphologically aberrant yet intrinsically stable
capsid.
Our results indicate an interesting trend with res-
pect to late RT step with the mutants H12Y, Q137R and
D202G. These mutants demonstrate a higher second
strand synthesis activity at 2 hr time point when com-
pared to that of wild type. The activity of these mutants
peaks at 2 hr time point, and shows a precipitous decline
at 6 hr time point. On the contrary, the activity of wild
type DNA synthesis shows a lag phase at 2 hr time
point, and shows a peak activity at 6 hr time point. This
result suggests that in the mutants, viral DNA synthesis
may start prematurely, but is unstable and hence the
DNA gets degraded. This phenotype indicates a role for
IN-INI1 binding in preventing the premature second
strand synthesis and for stabilizing the late RT products.
However, further work is needed to understand the me-
chanism underlying this differential kinetics of RT
(Figure 3, Panel D). K71R, on the other hand, appears
to have an overall low level of DNA synthesis.
At this point we cannot determine if INI1 has a direct
role in reverse transcription. The effect of IID-IN muta-
tions could be indirect and could affect the protein fold-
ing leading to defects in assembly, morphogenesis and
reverse transcription. However, it is interesting to note
that the phenotype we observe for D202 and other IID-
IN mutants are similar to the phenotype observed for
particles produced in MON cells, the INI1-/- rhabdoid
tumor cells [26]. The HIV-1 particles produced in MON
are severely impaired for infection with a block occur-
ring at or prior to reverse transcription. These studies
indicate that lack of INI1 in the producer cells makes
the particles defective for reverse transcription. While
these studies argue for a role of INI1 and/or INI1-as-
sociated complexes in reverse transcription, further stu-
dies are required to determine the effect of INI1 on
particle assembly and morphogenesis. Since INI1 is
likely to bind to the IN portion of Gag-Pol, these studiesmay uncover a specific and distinct role of Gag-Pol du-
ring late events.
Partially defective IID-IN mutants, S147G, and K111E
were less defective for reverse transcription and 2LTR
circle formation, suggesting that partial retention of
INI1 binding is enough to proceed through these steps.
These mutants did not exhibit any defect in binding
to other host factors. The partially defective mutants
however were defective for integration. The defect in in-
tegration is partial and correlated with the degree of de-
fect of these mutants for binding to INI1. Interestingly,
both S147G and K111E retain their in vitro integration
activity, while the highly defective mutants either did
not express stable proteins in bacteria or were defective
for integration activity (data not shown). However, the
observed results obtained with partially defective IN mu-
tants are consistent with the idea that IN-INI1 inter-
action is necessary for integration in vivo. The IN-INI1
interaction has been strongly implicated in recent fin-
dings as a necessary component of full-site integration
into chromatinized DNA in vitro [28]. It was reported
that both SWI/SNF chromatin remodeling activity and
the presence of INI1 in the active SWI/SNF complex,
are required for efficient and competent integration in
an in vitro nucleosome model [28]. These results suggest
that binding of IN to INI1 within the SWI/SNF complex
is required for integration into chromatinized target.
Our in vivo results support this finding and strongly sug-
gest that full binding between IN and INI1 are necessary
to efficiently complete integration. Future studies identi-
fying mutants that are specifically defective for INI1
binding and those that are not defective for integration
in vitro, are likely to shed light on the role of INI1 in
integration.
The question is how does INI1 play a role in assembly,
reverse transcription and integration of HIV-1. One pos-
sibility is that binding of INI1 to Gag-Pol could allow
proper assembly and morphogenesis. Subsequent to par-
ticle production, the IN-INI1 interaction is maintained in
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could influence reverse transcription in the cytoplasm and
integration in the nucleus. INI1 has been found in the
purified and subtilisin treated HIV-1 virions and it has
been found in purified reverse transcription complexes
within the infected cells [42]. INI1 has multiple cellular
functions as indicated by numerous protein-protein inter-
actions, non-specific DNA binding. It is possible that spe-
cific functions of INI1 may affect distinct stages of the
HIV-1 life cycle. Assembly of Gag-Pol with INI1 and its
incorporation into virions along with associated SAP18
and HDAC1 may play a role in early reverse transcription.
Indeed, we have demonstrated that incorporation of cata-
lytically inactive mutants of HDAC1 into HIV-1 virions
leads to defect in reverse transcription [29]. Subsequently,
INI1 may assist IN with integration in the nucleus.
Our previous studies have demonstrated that INI1
mutants defective for dimerization and DNA binding
activity exhibited reduced activity to stimulate in vitro
integration, and defect in DNA binding correlated to their
impairment in stimulating integrase activity in vitro [43].
These studies suggest that DNA binding activity of INI1
may be required for integration. Based on these ob-
servations, we speculate that while the ability of INI1
to mediate protein-protein interactions may be im-
portant to facilitate late events of HIV-1 replication
and proper particle morphogenesis, once INI1 is as-
sociated with IN, its ability to bind to DNA may be
important to facilitate integration. Thus, distinct func-
tions of INI1 may contribute to different steps of
HIV-1 replication. Therefore, lack of INI1 or lack of
interaction with INI1 may lead to multiple blocks to
HIV-1 replication.
One of the mutants recovered during our reverse two
hybrid screen was K71R; this mutant was previously
identified as an INI1-interaction defective mutant of IN
[31]. This study indicated that K71R mutant was more
replication competent than wild type. However, in our
hands, multiple assays testing for replication (multiday
replication assay, single cycle infection assay, early and
late reverse transcription assays and in vivo integration
assays) of this mutant indicated it to be partially defect-
ive. We noted that during multiday replication, many of
the mutants readily reverted to wild type after the first
round of replication. For example, S147G, a partially de-
fective mutant showed slow replication in the first round
of replication in a multiday replication assay. However,
continued cultures for more than 14 days resulted in in-
creased replication. Sequence analysis of the virions
from this culture indicated that S147G virus has reverted
to true wild type (data not shown). Therefore, we specu-
late that either difference in the assays used in our two
studies or reversion could account for the observed dif-
ferences in the two results.In summary, we find that IN mutants defective for
binding to INI1 exhibit defects at early post-entry events
and at integration. The observed defects at reverse tran-
scription are consistent with the previous observations
of the effects of lack of INI1 or mutations in INI1-
associated HDAC1 [26,29]. Furthermore, the highly de-
fective mutants exhibited aberrant virion morphology.
These results suggest that interaction of IN within the
context Gag-Pol with INI1 is necessary for proper as-
sembly and virion morphogenesis. Defects in these
events could manifest as defects in early reverse tran-
scription. However, the partially defective IID-IN mu-
tants that have normal virion morphology are partially
defective for DNA synthesis and integration. The genetic
studies carried out thus far indicate that disrupting IN-
INI1 interaction results in dramatic inhibition of HIV-1
replication: (1) sequestering IN by using a dominant
negative mutant of INI1 results in potent inhibition of
late events [21]; (2) INI1-/- cells are defective for particle
production and those particles that are produced are de-
fective for early events [26]; (3) IN mutants that are de-
fective for INI1 binding result in dramatic effects in
HIV-1 replication (the current study). Since strong dis-
ruption of the IN-INI1 interaction leads to multiple
blocks at reverse transcription and integration, the vi-
rions are severely compromised for replication.
Conclusions
We have found that IN mutants defective for binding to
INI1 exhibit defects in particle morphogenesis, early
post entry events and/or integration. We propose that
INI1 binding to Gag-Pol facilitates proper assembly of
the complex, which is required for subsequent post-
entry events in the target cells. Thus, we propose that
disrupting IN-INI1 interactions may lead to the inhi-
bition of multiple steps of viral replication.
Methods
Cells and reagents
293 T and HeLa cells (ATCC) were cultured in Dulbecco’s
modified Eagle medium (DMEM) and supplemented
with 10% FBS, L-glutamine, and Pen-strep. CEM-GFP
cells were grown in RPMI1640 containing 10% FBS, L-
glutamine, Pen-strep and supplemented with 500 μg/mL
G418.
Isolation of IID-IN mutants by using reverse yeast
two-hybrid system
A random mutation library of HIV-1 IN was generated
by using PCR-based mutagenesis utilizing the error-
prone nature of TaqMan polymerase [30]. Specifically, a
two-hybrid plasmid vector carrying wild type IN fused
to the GAL4-Activation domain (GAL4-AD in plasmid
pGADNot-IN [30,44], was mutagenized by using TaqMan
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nized plasmid pool was co-transformed into yeast with a
plasmid expressing INI1 fused to LexA DNA Binding do-
main (LexADB-INI1 in plasmid pSH2-INI1 [23]. A panel
of INI1-interaction defective IN (IID-IN*) mutants were
isolated that resulted in white colonies in the X-gal assay.
Plasmid harboring mutant IN (pGADNot-IID-IN*) iso-
lated from yeast, were retransformed into yeast along with
pSH2-INI1 to confirm the interaction-defective pheno-
type. The clones were sequenced to determine the pre-
sence of mutations.Generation of HIV-1NL4-3 full-length and HIV-Luc viral
clones harboring IID-IN mutations
HIV-1NL4-3 viral clones containing IID-IN mutations
were generated in two stages. First, a 2.3 Kb Age I (posi-
tion 3485 bp) and Sal I (position 5785 bp) fragment of
HIV-1NL4-3 containing the IN open reading frame was
subcloned into the pEGFPN1 vector to generate an
intermediate vector pEGFPN1-IN-int. IID-IN muta-
tions were introduced into pEGFPN1-IN-int using
the QuickChange II Mutagenesis Kit (Stratagene). The
Sal I/Age I fragment containing the desired mutation
was subsequently cloned into pNL4-3 as well as
pNL4-3.Luc.R-E-(HIV-Luc) to obtain mutant viral clones
for use in multiday and single cycle infection assays.Construction of YFP-IID-IN mutant expression plasmids
IID-IN mutants were introduced into a previously de-
scribed vector encoding IN fused to YFP [25] using
QuickChange Lightening site-directed mutagenesis kit










TG-3’); S147G (Forward 5’-CCCTACAATCCCCAAGGT
CAAGGAGTAGTAGAATCTATG-3’) (Reverse 5’-CATA
GATTCTACTACTCCTTGACCGTTGGGATTGTAGG
G-3’); K111E (Forward 5’-GGAAGATGGCCAGTAGA
AACAATACATACAGACAATGGC-3’) (Reverse 5’-GCC
ATTGTCTGTATGTATTGTTTCTACTGGCCATCTT
CC-3’). YFP-D202G (Forward 5’-GCAGGGGAAAGAA
TAGTAGGCATAATAGCAACAGAC-3’) (Reverse 5’-GTC
TGTTGCTATTATGCCTACTATTCTTTCCCCTGC-3’).Construction of plasmids expressing 6His-IID-IN
To construct pQE32-IID-IN* mutant plasmids express-
ing 6His-tagged IID-IN mutants, the GFP-IN constructs
were used as template and IN sequences were PCR amp-
lified using the following primers containing Bam HI
and Sal I restriction sites: YFP-C3-INForward 5’-GG
TACCGCGGGCCCGCGGATCCACTTTTTAGATGGA
ATAGATAAGGCCC-3’ and YFP-C3Reverse 5’-GATC
CGGTGGAAGATCTGTCGACCTTAATCCTCATCCT
GTCTACTTGC-3’. The PCR product was cloned into
the pQE32 vector (Qiagen) and transformed into E.
coli strain M15 (pDM1) for expression of protein.
Purification of 6His-IID-IN mutants and GST-tagged
proteins
1 L cultures of 6His-IID-IN mutants were grown to an
OD600 of ~0.8 before induction with 1 mM IPTG for 3-
6 hours at 37°C. The cell pellet from 1 L of culture was
resuspended in 20 mL of lysis buffer A (50 mM NaPO4
pH 7.4, 0.1 mM EDTA, 5% glycerol, 10 mM β-ME,
1 mM PMSF) and spun at 17,000 × g for 10 min. Lyso-
zyme was added to a final concentration of 1 mg/mL
and incubated for 30 min at 4°C before adding NaCl to a
final concentration of 1 M. Lysates were incubated
30 min at 4°C, then sonicated three times for 1 min
each, with cooling intervals. Sonicated lysates were then
passed through a 21G1.5 syringe needle twice and
centrifuged at 52,000 × g for 30 min at 4°C. Clarified
supernatant was then collected and used for binding
assays.
GST, GST-INI1, GST-IN, GST-RT-p51 and GST-
SAP18 proteins bound to G-beads were prepared as
previously described [23]. The GST-p51 construct was
prepared by PCR amplifying RT sequence from HIV-1
NL4-3 using the following primers containing Bam HI
and Eco RI restriction sites: (p51 Forward 5’-CCGG
GATCCCGCCCATTAGTCCTATTGAGACTGTACCA
GTA-3’), (p51 Reverse 5’-CGGAATTCGAAAGTTTC
TGCTCCTATTATGGG-3’). GST-LEDGF (a gift from
Dr. Alan Engelman) and GST-GEMIN2 (a gift from Dr.
Gideon Dreyfuss) were purified in a similar manner as
described above with slight differences. GST-LEDGF in
BL21 cells were grown to an OD600 ~0.9 at 37°C be-
fore induction with 0.5 mM IPTG for an additional
3 hours at 28°C. Pellets from 250 mL cultures were
resuspended in 10 mL of low salt buffer: 50 mM NaCl,
50 mM Tris-Cl pH 7.5, 1 mM EDTA, 0.5% IGEPAL,
5 mM DTT, and one Complete mini protease inhibi-
tor cocktail tablet (Roche) per 10 mL buffer. GST-
GEMIN2 was isolated similar to GST-LEDGF with
slight differences in low salt lysis buffer (50 mM NaCl,
25 mM Tris-Cl pH 7.5, 1 mM EDTA, 2 mM DTT,
protease inhibitor tablet).
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5 μg of GST-tagged proteins bound to glutathione seph-
arose 4B beads were incubated for 1 hour at 4°C with
normalized amounts of either clarified bacterial cells ly-
sates containing 6His-WT-IN and 6His-IID-IN mutants
in binding buffer (20 mM HEPES-KOH pH 8.0, 5 mM
DTT, 0.1% IGEPAL, protease inhibitor tablet) or mam-
malian cell extract expressing YFP-fusions of IID-IN
mutants. Following incubation, beads were washed 5-7
times with buffer containing 50 mM Tris-Cl pH 8.0,
0.1 mM EDTA, 200 mM NaCl, 0.5% IGEPAL, 25 mM
PMSF. Bound proteins were separated by SDS-PAGE
and analyzed using indicated antibodies. The relative
binding was quantified by using densitometry (Odyssey
infrared imaging system, LI-COR). Briefly, the fraction
of protein bound was determined for each clone com-
pared to the signal in the loading control. Relative bind-
ing was determined by comparing the binding ability of
mutants to that of the wild type protein.
To test binding of IID-IN mutants to INI1, 293 T cells
were transfected with 5 μg YFP-IN or YFP-IID-IN mu-
tant DNA (in pEYFP-C3 vector). Whole cell lysates were
collected 48 hours post-transfection and normalized for
YFP-IN levels using Western blot probed for IN. Clari-
fied lysates, containing normalized levels of YFP-IN or
YFP-IID-IN, were then incubated with 5 μg of GST-
tagged INI1, bound to glutathione sepharose 4B beads,
and incubated for 1 hour at 4°C. Pull-down reactions
were performed as described above.Virus production
Viral stocks of full-length HIV-1 and HIV-Luciferase
(HIV-Luc) were prepared by transient transfection of 50-
60% confluent 293 T cell monolayers in 100 mm plates
with 10 μg pNL4-3, or cotransfection of 5 μg pNL4-3.
Luc. R-E- (deleted for env) and 5 μg VSV-G plasmid
DNA (courtesy of Dr. Nathaniel Landau, NIH AIDS
Research and Reference Reagent Program). Virus was
collected 48 hours post-transfection and clarified by pass-
ing through a 0.45 μm cellulose acetate filter (Corning).
Clarified supernatant was then treated for 30 minutes with
20 units DNaseI (Roche)/mL supernatant at 37°C. Viral
stocks were measured for p24 using a p24 enzyme-linked
immunosorbent assay (ELISA) (Advanced Bioscience
Laboratories).Multiday replication
25 ng p24 of each HIV-1NL4-3 IID-IN mutant and WT
were used to infect 200,000 CEM-GFP cells for 2 hours
in a 2 mL culture. After incubation with virus, 18 mL of
complete RPMI1640 was added to the culture in a
75 cm2 flask. 1 mL of culture was collected every two
days for 16 days. Viral replication was monitored byobserving cellular GFP levels and by measuring p24
levels in the culture supernatant.Luciferase assays
Cells infected with HIV-Luciferase were assayed 24
hours post-infection using the Luciferase Assay System
(Promega) following the manufacturer’s instructions.Exogenous RT assay
500 ng p24 of HIV-1NL4-3 WT and IID-IN mutants were
PEG precipitated overnight at 4°C and centrifuged at
16,000 × g, 45 min, at 4°C. Viral pellets were lysed in
12.5 μL solution B (0.9% Triton X-100, 440 mM KCl)
and vortexed for 1 minute before adding 50 μL solution
A (25 mM Tris pH 7.8, 0.25 mM EDTA, 0.025% Triton
X-100, 50% glycerol, 2 mM DTT, 100 mM KCl). 10 μL
of each lysate was incubated with 40 μL of an RT reac-
tion cocktail (50 mM Tris pH 8.0, 10 mM DTT, 60 mM
NaCl, 10 μg/mL oligo-dT, 100 μg/mL poly-rA, 100 μM
dTTP, 1 mCi/μL α32P-dTTP, and 10 mM MgCl2) for
1 hour at 37°C. 10 μL of each reaction was then spotted
on DEAE paper, washed and measured in a scintillation
counter.Isolation of HIV-1 cores and in vitro uncoating assay
Cores were isolated from concentrated virions as previ-
ously described [37]. Briefly, virus supernatants from
transfected 293 T cells were concentrated by centrifuga-
tion at 32,000 rpm (175,000 × g at rmax) for 3 hours at
4°C. Viral pellets were resuspended in 300 μl of 1X STE
buffer (10 mM Tris–HCl [pH 7.4], 0.1 M NaCl, 1 mM
EDTA) and incubated at 4°C for at least 2 hours to allow
small clumps of virus to disperse. Concentrated virions
were then ultracentrifuged (187,000 × g at rmax for
16 hours at 4°C) through a 30-70% sucrose gradient
overlaid with 1% Triton X-100. Fractions (1 ml) were
collected from top of the sucrose gradient and CA con-
tent of the fractions was determined by p24 ELISA.
For the in vitro uncoating assay, samples of purified
wild-type and mutant HIV-1 cores (50 μl, containing
~50 ng of p24) were diluted in 1X STE buffer, pH 7.4
(200 μl). The reactions were then incubated at 37°C
for indicated times followed by ultracentrifugation at
45,000 rpm (Beckman TLA-55 rotor, 125,000 × g at rmax)
for 20 min at 4°C. Supernatants were removed and
pellets were dissolved in sample diluent (10% Donor
Calf Serum and 0.5% Triton X-100 in phosphate–buf-
fered saline). CA content of supernatants and pellets
was measured by p24 ELISA. The extent of uncoa-
ting was determined as the percentage of CA content
of supernatant to the total quantity of CA in the
reaction.
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50% confluent 293 T cells were spinoculated with 20 ng
p24 of HIV-Luc virus for 2 hours at 15°C and spun at
400 × g. Cells were collected at various time points post-
infection and harvested for genomic DNA using the
DNeasy Blood and Tissue Kit (QIAGEN). All genomic
DNA samples were normalized and 300-500 ng DNA was
used per 50 uL real-time PCR reaction containing 300
nM primers, 100 nM probe and 2× Taqman Universal
Master Mix (Applied Biosystems). Primers and probes
to detect early and late RT products are as follows
[45]: Early RT primers, ert2f 5’-GTGCCCGTCTG
TTGTGTGAC-3’, ert2r 5’-GGCGCCACTGCTAGAGAT
TT-3’, and ert2 probe 5’-CTAGAGATCCCTCAGACC
CTTTTAGTCAGTGTGG-3’. Late RT primers, MH531
forward 5’-TGTGTGCCCGTCTGTTGTGT-3’ , MH532
reverse 5’-GAGTCCTGCGTCGAGAGAGC-3’ , and LRT
probe 5’-CAGTGGCGCCCGAACAGGGA-3’. Cycling
conditions on an ABI 7900HT are 2 min at 50°C, 10 min
at 95°C, followed by 40 cycles of 15 sec at 95°C and
1 min at 60°C. Primers and probes to detect 2LTR circles
are as follows: MH535 forward 5’-AACTAGGGAAC
CCACTGCTTAAG-3’ , MH536 reverse 5’-TCCACAGA
TCAAGGATATCTTGTC-3’ , and MH603 probe 5’-
ACACTACTTGAAGCACTCAAGGCAAGCTTT-3’.
To detect the integrated provirus, nested Alu-PCR was
performed [46]. The products were measured by iso-
lating genomic DNA 24 hours post-infection and
performing nested PCR. In the first semi-quantitative
PCR round, Alu-gag was amplified as described [46].
Real-time PCR, using the MH531, MH532, and late RT
primers and probe, was then performed on products
from the first round PCR using conditions described
above. Standard curves were generated by isolating gen-
omic DNA from 293 T cells stably infected with HIV-1
containing GFP and a hygromycin-resistance marker
[46] and performing nested PCR from this cell line. Ct
values were then plotted against dilutions of the
hygromycin-resistant HIV-1 plasmid to create a standard
curve.
Western blots
Whole cell extract from 293 T cells transfected with
pNL4-3 WT and IID-IN mutant plasmids were collected
after lysing with RIPA buffer. Culture supernatant con-
taining virus was centrifuged over a 20% sucrose cushion
at 112,000 × g for 2 hours at 15°C. The viral pellet was
washed once with PBS before resuspension in PBS and
HEPES. Normalized amounts of p24 from each virus
prep was precipitated with a 30% PEG8000/0.4 M NaCl
solution and resuspended in lysis buffer containing
50 mM Tris-Cl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1%
IGEPAL, 1% Triton X-100, 0.5% sodium deoxycholate,0.5 M PMSF. Viral proteins and cell lysates were re-
solved by SDS-PAGE and analyzed by Western blot with
indicated antibodies.
Transmission electron microscopy
293 T cells in a 6-well format were transfected with 2ug
each of the indicated pNL4-3 either WT or IID-IN mu-
tant plasmids using the Mammalian Cell Transfection
kit (Millipore Catalogue #s-001). Media was changed
16 hours post-transfection and cells were fixed 6 hours
post-media change with buffer containing 2.5% glutaral-
dehyde in 0.1 M sodium cacodylate buffer, postfixed
with 1% osmium tetroxide followed by 2% uranyl acet-
ate, dehydrated through a graded series of ethanol and
embedded in LX112 resin (LADD Research Industries,
Burlington VT). Ultrathin sections were cut on a Reichert
Ultracut UCT, stained with uranyl acetate followed by lead
citrate and viewed on a JEOL 1200EX transmission elec-
tron microscope at 80kv.
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